126
|
Schuler M, Yang JH, Sequist L, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Hirsh V, Mok T, Wu YL. Overall Survival (OS) with Afatinib (A) Vs Chemotherapy (CT) in Patients (PTS) with Nsclc Harbouring EGFR Mutations (MUT): Subgroup Analyses by Race in Lux-Lung 3 (LL3) and Lux-Lung 6 (LL6). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
127
|
Pöttgen C, Stuschke M, Gauler T, Friedel G, Veit S, Heinzelmann F, Welter S, Spengler W, Schmidberger H, Lütke-Brintrup H, Jöckel K, Schuler M, Stamatis G, Eberhardt W. PO-0674: Brain relapses in stage III NSCLC after multimodality treatment: prognostic factors from a randomised trial. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40666-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
128
|
Schuler M, Yang JH, Park K, Chand V, Wang B, Planchard D. Afatinib (A) Plus Paclitaxel (P) Following Progression on a Monotherapy in Patients (PTS) with Metastatic Non–Small-Cell Lung Cancer (NSCLC) Who Previously Benefited From Erlotinib (E)/Gefitinib (G): a Global Randomised Phase Iii Trial–Lux-Lung 5 (LL5). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv050.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
129
|
Gautschi O, Bluthgen M, Smit E, Wolf J, Früh M, Peters S, Schuler M, Zalcman G, Milia J, Mazieres J. Targeted Therapy for Braf-Mutant Lung Cancer: Results from the European Euraf Cohort Study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv128.07] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
130
|
Ma B, Bang YJ, Lim WT, Nam DH, Su WC, Schellens J, Azaro A, Akimov M, Zhang Y, Kumar A, Zhao S, Schuler M. Phase I dose escalation and expansion study to evaluate safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv090.4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
131
|
Reis H, Herold T, Ting S, Worm K, Huber U, Christoph DC, Eberhardt WE, Kostbade K, Kasper S, Stamatis G, Welter S, Darwiche K, Karpf-Wissel R, Theegarten D, Schmid KW, Schuler M, Wiesweg M. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. Lung Cancer 2015; 88:34-41. [PMID: 25708529 DOI: 10.1016/j.lungcan.2015.02.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Revised: 01/04/2015] [Accepted: 02/01/2015] [Indexed: 11/25/2022]
Abstract
OBJECTIVES Pulmonary adenocarcinomas (ADC) can be sub-grouped based on dominant oncogenic drivers. EGFR mutations define an entity of metastatic ADC with favorable prognosis and high susceptibility to EGFR tyrosine kinase inhibition. In contrast, the clinical impact of additional ERBB family members in ADC is less defined. To this end we prospectively studied HER2 expression, gene amplification, and mutation in relation to outcome of patients with advanced or metastatic ADC. MATERIALS AND METHODS Diagnostic tumor biopsies from 193 sequential patients with stage III/IV ADC were prospectively studied for HER2 expression by immunohistochemistry (IHC). Cases with IHC scores 2+ or 3+ were analyzed by HER2 chromogenic in situ hybridization (CISH), and sequencing of HER2 exons 20 and 23. Additional prospectively determined biomarkers included PTEN, cMET, pAKT, and pERK expression, KRAS, EGFR, BRAF and PIK3CA mutations, and ALK fluorescence ISH (FISH). RESULTS AND CONCLUSION HER2-IHC was feasible in 176 (91.2%) cases. Of 53 (30%) cases with IHC scores 2+/3+, 45 (85%) could be studied by CISH and 34 (64%) by sequencing. The lower number of HER2-mutational analyses resulted from exhaustion of tumor tissue and DNA following mutational analysis of KRAS, EGFR, BRAF and PIK3CA. HER2 amplification was detected in 4 cases (2.3%), while no mutation was found. HER2 expression correlated with expression of pAKT and cMET. Expression of HER2 and pAKT was associated with favorable overall survival in stage IV disease. HER2-expressing ADC more frequently harbored KRAS mutations, while HER2 expression was absent in all 4 cases with BRAF mutation. HER2-IHC was not predictive of HER2 gene amplification or mutation, which both were rare events in prospectively studied patients with advanced or metastatic ADC. Expression of HER2 and pAKT define a population of patients with stage IV ADC with a distinct disease course, who could benefit from specifically tailored pharmacotherapies.
Collapse
|
132
|
Wittmann M, Jelusic D, Schuler M, Schultz K. Unterschätzen wir den COPD-Schweregrad von Frauen bei ausschließlich spirometrischer Lungenfunktionsmessung wegen einer stärker ausgeprägten Emphysem-Komponente? Ein Plädoyer für die Diffusionsmessung. Pneumologie 2015. [DOI: 10.1055/s-0035-1544720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
133
|
Schuler M, Planchard D, Yang JC, De Marinis F, Bennouna J, Kim JH, Chouaid C, Wiewrodt R, Grossi F, Feng J, Strausz J, Lu S, Kim DW, Liu X, Chen YM, Zhou C, Wang B, Chand VK, Park K. Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung 5 (LL5). Pneumologie 2015. [DOI: 10.1055/s-0035-1544761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
134
|
Schwaighofer B, Jelusic D, Wittmann M, Schuler M, Schultz K. Psychische Komorbidität bei COPD Patienten: Welche Langzeiteffekte zeigen sich nach einer stationären pneumologischen Rehabilitation? Pneumologie 2015. [DOI: 10.1055/s-0035-1544675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
135
|
Jelusic D, Wittmann M, Schuler M, Schultz K. Subjektive Bewertung einzelner Komponenten der pneumologischen Rehabilitation durch COPD-Patienten bei Entlassung und nach einem Jahr. Pneumologie 2015. [DOI: 10.1055/s-0035-1544677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
136
|
Schultz K, Jelusic D, Wittmann M, Schuler M. Lebensqualität und Dyspnoe von COPD-Patienten 1 Jahr nach stationärer pneumologischer Rehabilitation. Pneumologie 2015. [DOI: 10.1055/s-0035-1544773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
137
|
Wingart S, Lehbert N, Leithäuser A, Sachse C, Jelusic D, Wittmann M, Schultz K, Schuler M. Können Mitarbeiter (MA) oder Patienten (Pat.) voraussagen, ob sich die 6-Minuten-Gehstrecke (6MGS) bei einem Wiederholungs-6-Minuten-Gehtest (W-6MGT) relevant verbessert? Pneumologie 2015. [DOI: 10.1055/s-0035-1544875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
138
|
Jelusic D, Wittmann M, Schuler M, Schultz K. Wie wirkt sich fortgesetzte und regelmäßige sportliche Aktivität auf Dyspnoe (TDI) und Lebensqualität (CAT) von COPD-Patienten ein Jahr nach stationärer pneumologischer Rehabilitation (PR) aus? Pneumologie 2015. [DOI: 10.1055/s-0035-1544674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
139
|
Lehbert N, Wingart S, Leithäuser A, Sachse C, Jelusic D, Schuler M, Wittmann M, Schultz K. 6-Minuten-Gehtest (6MGT) und Sit-to-Stand Test (STST) als Outcome-Parameter der Pneumologischen Rehabilitation (PR) bei COPD. Pneumologie 2015. [DOI: 10.1055/s-0035-1544669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
140
|
Schultz K, Wittmann M, Jelusic D, Huber V, Krämer B, Fuchs S, Wingart S, Lehbert N, Stojanovic D, Schuler M. Erste Lungenfunktionsergebnisse der RIMTCOR-Studie (routinemäßiges Inspirationsmuskeltraining im Rahmen der COPD-Rehabilitation) – eine randomisierte real life Studie (RCT). Pneumologie 2015. [DOI: 10.1055/s-0035-1544776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
141
|
Mehl S, Ferstl P, Schuler M, Toghan A, Brummel O, Hammer L, Schneider MA, Libuda J. Thermal evolution of cobalt deposits on Co3O4(111): atomically dispersed cobalt, two-dimensional CoO islands, and metallic Co nanoparticles. Phys Chem Chem Phys 2015; 17:23538-46. [DOI: 10.1039/c5cp03922c] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Cobalt deposition onto Co3O4(111) leads to formation of atomically dispersed cobalt species, which form ordered two-dimensional oxide islands upon annealing.
Collapse
|
142
|
Andreou D, Werner M, Pink D, Traub F, Schuler M, Gosheger G, Jobke B, Reichardt P, Tunn PU. Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma. Br J Cancer 2014; 112:455-60. [PMID: 25535732 PMCID: PMC4453655 DOI: 10.1038/bjc.2014.635] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2014] [Revised: 11/01/2014] [Accepted: 12/01/2014] [Indexed: 11/21/2022] Open
Abstract
Background: We sought to examine whether mitotic count (MC) and the amount of viable tumour (VT) following neoadjuvant systemic chemotherapy (SC) for primary, localised, high-grade soft tissue sarcoma (STS) correlate with prognosis. Methods: Retrospective analysis of 57 patients who underwent SC involving a combination of an anthracycline and an alkylating agent, followed by surgical resection between 2001 and 2011. Results: The amount of VT after chemotherapy was significantly associated with disease-specific survival (DSS) and event-free survival (EFS). Patients with <10% VT had a DSS of 94% at 5 years, compared with 61% for patients with ⩾10% VT (P=0.033); EFS was 75%, compared with 48% (P=0.030). Patients with an MC of ⩾20/10 high power fields (HPF) after chemotherapy had a significantly lower DSS (33% vs 84% at 5 years, P<0.001) and EFS (40% vs 63% at 5 years, P=0.019) than patients with an MC of <20/10 HPF. Conclusions: The MC and the amount of VT after neoadjuvant therapy for primary, localised, high-grade STS appear to correlate with prognosis. If these results are validated prospectively, then they could provide a rational for the design of neoadjuvant treatment modification/escalation studies, analogue to the EURAMOS-1 trial for bone sarcomas.
Collapse
|
143
|
Göbel C, Breitenbuecher F, Kalkavan H, Hähnel PS, Kasper S, Hoffarth S, Merches K, Schild H, Lang KS, Schuler M. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis 2014; 5:e1568. [PMID: 25501829 PMCID: PMC4649842 DOI: 10.1038/cddis.2014.531] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 11/03/2014] [Accepted: 11/04/2014] [Indexed: 02/06/2023]
Abstract
The efficacy of immune surveillance and antigen-specific cancer immunotherapy equally depends on the activation of a sustained immune response targeting cancer antigens and the susceptibility of cancer cells to immune effector mechanisms. Using functional expression cloning and T-cell receptor (TCR) transgenic mice, we have identified cyclooxygenase 2/prostaglandin-endoperoxide synthase 2 (COX-2) as resistance factor against the cytotoxicity induced by activated, antigen-specific T cells. Expressing COX-2, but not a catalytically inactive COX-2 mutant, increased the clonogenic survival of E1A-transformed murine cancer cells when cocultured with lymphocytes from St42Rag2−/− mice harboring a transgenic TCR directed against an E1A epitope. COX-2 expressing tumors established in immune-deficient mice were less susceptible to adoptive immunotherapy with TCR transgenic lymphocytes in vivo. Also, immune surveillance of COX-2-positive tumor cells in TCR transgenic mice was less efficient. The growth of murine MC-GP tumors, which show high endogenous COX-2 expression, in immunocompetent mice was effectively suppressed by treatment with a selective COX-2 inhibitor, celecoxib. Mechanistically, COX-2 expression blunted the interferon-gamma release of antigen-specific T cells exposed to their respective cellular targets, and increased the expression of interleukin-4 and indoleamine 2,3-dioxygenase by tumor cells. Addition of interferon-gamma sensitized COX-2 expressing cancer cells to tumor suppression by antigen-specific T cells. In conclusion, COX-2, which is frequently induced in colorectal cancer, contributes to immune evasion and resistance to antigen-specific cancer immunotherapy by local suppression of T-cell effector functions.
Collapse
|
144
|
Shaw A, Mehra R, Tan DSW, Felip E, Chow LQM, Ross Camidge D, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Geraldes M, Sen P, Boral AJ, Yovine A, Kim DW. BM-32 * CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou240.32] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
145
|
Tabernero J, van Geel R, Bendell J, Spreafico A, Schuler M, Yoshino T, Delord J, Yamada Y, Lolkema M, Faris J, Eskens F, Sharma S, Yaeger R, Lenz H, Wainberg Z, Avsar E, Chatterjee A, Jaeger S, Demuth T, Schellens J. 11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70732-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
146
|
Kim D, Mehra R, Tan D, Felip E, Chow L, Camidge D, Vansteenkiste J, Sharma S, De Pas T, Riely G, Solomon B, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Geraldes M, Boral A, Yovine A, Shaw A. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.08.208] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
147
|
Juric D, Burris H, Schuler M, Schellens J, Berlin J, Seggewiß-Bernhardt R, Gil-Martin M, Gupta A, Rodon J, Tabernero J, Janku F, Rugo H, Bootle D, Quadt C, Coughlin C, Demanse D, Blumenstein L, Baselga J. Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.11] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
148
|
Trarbach T, Schuler M, Zvirbule Z, Lordick F, Krilova A, Helbig U, Schulze-Bergkamen H, Thuss-Patience P, Wichert G, Schmiegel W, Bauer S, Müller C, Al-Batran S, Huber C, Maurus D, Kühnle M, Sahin U, Türeci Ö. Efficacy and Safety of Multiple Doses of Imab362 in Patients with Advanced Gastro-Esophageal Cancer: Results of a Phase Ii Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.21] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
149
|
Stuschke M, Pöttgen C, Gauler T, Friedel G, Veit S, Heinrich V, Welter S, Spengler W, Schmidberger H, Lütke-Brintrup D, Lehmann N, Jöckel K, Schuler M, Stamatis G, Eberhardt W. Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) Versus Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) With Operable Stage IIIA(N2)/Selected IIIB Non-small-Cell Lung Cancer (NSCLC) Following Induction Chemotherapy (IND-C): Results From a Multicenter Phase III Study. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
150
|
Felip E, Kim D, Mehra R, Tan D, Chow L, Camidge D, Vansteenkiste J, Sharma S, De Pas T, Riely G, Solomon B, Wolf J, Thomas M, Schuler M, Lui G, Santoro A, Geraldes M, Boral A, Yovine A, Shaw A. Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.74] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|